A phase II study of docetaxel and vinorelbine combination chemotherapy in patients with advanced non-small cell lung cancer

European Journal of Cancer

Volumn 36, Issue 9, 2000, Pages 1107-1112

  Bennouna, J ^a   Monnier, A ^b   Riviere A ^c   Milleron, B ^d   Lemarie, E ^e   Trillet Lenoir, V ^f   Soussan Lazard, K ^g   Berille, J ^g   Douillard, J Y ^a  

^a CENTRE RENÉ GAUDUCHEAU   (France)

^b Service de Chirurgie Générale et Digestive   (France)

^c CENTRE FRANÇOIS BACLESSE   (France)

^d HÔPITAL TENON   (France)

^e CHU BRETONNEAU   (France)

^f CENTRE HOSPITALIER LYON SUD   (France)

^g SANOFI   (France)

Author keywords

Advanced non small cell lung cancer; Vinorelbrine doxetaxel combination

Indexed keywords

DIOSMIN; DOCETAXEL; GRANISETRON; METOCLOPRAMIDE; NAVELBINE; PREDNISOLONE;

ADULT; AGED; ALOPECIA; ANEMIA; ARTICLE; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; HUMAN; HYPERSENSITIVITY; LEUKOPENIA; LUNG NON SMALL CELL CANCER; MALE; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SEPTICEMIA; SIDE EFFECT; STOMATITIS; THROMBOCYTOPENIA;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; FOLLOW-UP STUDIES; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; NEUTROPENIA; PACLITAXEL; SURVIVAL RATE; TAXOIDS; TREATMENT OUTCOME; VINBLASTINE;

EID: 0034027969     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(00)00097-6     Document Type: Article

References (17)

1. Chemotherapy in non-small cell lung cancer. a meta-analysis using updated data on individual patients from 52 randomised clinical trials Br. Med. J. 311:1995;899-909.
2. Francis P.A., Rigas J.R., Kris M.G.et al. Phase II trial of docetaxel in patients with stage III and IV non-small-cell lung cancer. J. Clin. Oncol. 12:1994;1232-1237.
3. 2 dose of docetaxel with prednisone premedication for patients with advanced non-small cell lung cancer. Cancer. 75:1995;968-972.
4. Cerny T., Kaplan S., Pavlidis N.et al. Docetaxel (Taxotere) is active in non-small cell lung cancer. a phase II trial of the EORTC Early Clinical Trials Group (ECTG) Br. J. Cancer. 70:1994;384-387.
5. Fossella F.V., Lee J.S., Murphy W.K.et al. Phase II of docetaxel for recurrent or metastatic non-small cell lung cancer. J. Clin. Oncol. 12:1994;1238-1244.
6. Ringel I., Horwitz S.B. Studies with RP 56 976 (Taxotere). a semisynthetic analogue of Taxol J. Natl. Cancer Inst. 83:1991;288-291.
7. Jordan Ma., Thrower D., Wilson L. Mechanism of inhibition of cell proliferation by vinca-alkaloids. Cancer Res. 51:1991;2212.
8. Depierre A., Lemarie E., Dabouis G., Garnier G., Jacoulet P., Dalphin J.C. A phase II study of Navelbine (Vinorelbine) in the treatment of non-small cell lung cancer. Am. J. Clin. Oncol. 14:1991;115-119.
9. Hino M, Kobayashi K, Hayashihara K, et al. In vitro combination effect of docetaxel (RP56976) with vinca-alkaloids on cancer cell line. Proc Am Assoc Cancer Res 1995, 36, 299 (abstract 1780).
10. Aoe K, Ueoka H, Kiura K, et al. Synergistic effect of docetaxel (DCT) and vinorelbine (VNB) against in vitro growth of a human small-cell lung cancer line. Proc Am Assoc Cancer Res 1996, 37, 375 (abstract 2560).
11. Fumoleau P., Delecroix V., Perrocheau G.et al. Docetaxel in combination with vinorelbine as first line chemotherapy in patients with metastatic breast cancer. a phase I, dose finding Proc. Am. Soc. Clin. Oncol. 15:1996;232.
12. Miller A.B., Hoogstraten B., Staquet M., Winkler A. Reporting results of cancer treatment. Cancer. 47:1981;207-214.
13. Fleming T. One sample multiple testing procedure for phase II clinical trials. Biometrics. 38:1982;143-151.
14. Bunn P.A. Jr., Kelly K. New chemotherapeutic agents prolong survival and improve quality of life in non small cell lung cancer. a review of the literature and future directions Clin. Cancer Res. 5:1998;1087-1100.
15. Lillenbaum R.C., Langenberg P., Dickersin K. Single agent versus combination chemotherapy in patients with advanced nonsmall cell lung carcinoma. A meta-analysis of response, toxicity, and survival. Cancer. 82:1998;116-126.
16. Kourousis C., Androulakis N., Kakolyris S.et al. First-line treatment of advanced nonsmall cell lung carcinoma with docetaxel and vinorelbine. Cancer. 83:1998;2083-2090.
17. Fossella F.V., Lee J.S., Shin D.M.et al. Phase II of docetaxel for advanced or metastatic platinum refractory non-small cell lung cancer. J. Clin. Oncol. 13:1995;645-651.